Pliant Therapeutics, Inc.

NASDAQ:PLRX

Biotechnology

Healthcare
$0.81 -3.39%

-$0.04 today

Market cap
$50.14M
Beta
1.21
P/E (TTM)
-0.6
EPS (TTM)
-$1.83
52W Low $1.09High $1.95

Volume 0.15M

Average 0.49M

PLRX Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Pliant Therapeutics, Inc.NASDAQ: PLRX

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit turns negative

Q1 FY2026 gross profit was -$264K, compared with $0 a year earlier. Trailing-twelve-month gross profit was -$711K.

Context

  • Gross profit increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near -$264K or moves back toward the trailing-twelve-month quarterly average of -$177.75K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$264K— QoQ
Last fiscal yearDec 2025
-$1.7M— YoY
LTMMar 2026
-$711K-14.3% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
(1.7M) USD
Year-over-year change
—

Gross Profit vs competitors

How PLRX compares with its peers on the latest reported figures

  • PLRX's LTM Mar 2026 gross profit of -$711K is the lowest of the 10 companies compared; the peer median is $0.
  • Its year-over-year change of -14.3% is the 6th highest of 9, against a peer median of +34.2%.
PLRX Competitors Peer median
Gross Profit for PLRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MGNXMacroGenics, Inc.LTM Mar 2026$109.85M +16.2%-9.3%69.9%
STROSutro Biopharma, Inc.LTM Mar 2026$98.33M +52.1%+17.0%98.7%
COYACoya Therapeutics, Inc.LTM Mar 2026$7.92M +177.2%—99.8%
OVIDOvid Therapeutics Inc.LTM Mar 2026$7.09M +1193.2%+66.6%99.5%
GUTSFractyl Health, Inc. Common StockLTM Mar 2026$0 -100.0%——
WHWKWhitehawk Therapeutics IncLTM Mar 2026-$5K +100.0%——
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026-$151K -100.6%——
CLNNClene Inc.LTM Mar 2026-$244K -188.4%-29.4%182.1%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026-$666K ———
PLRXPliant Therapeutics, Inc.LTM Mar 2026-$711K -14.3%——
Peer median (excluding PLRX) $0+34.2%+3.8%99.5%

Competitors are the stored peer set for PLRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue7.57M9.69M1.58M00
Cost of Revenue00001.7M
Gross Profit7.57M9.69M1.58M0(1.7M)
Gross Margin100.0%100.0%100.0%——
Research & Development77.55M96.94M127.8M169.31M109.16M
Selling, General & Admin27.56M39.95M57.93M59.06M47.22M
Operating Expenses105.11M136.89M185.73M228.37M148.38M
Depreciation & Amortization1.54M3.68M1.84M2.13M1.7M
EBITDA(95.73M)(118.85M)(158.23M)(205.16M)(145.09M)
EBITDA Margin-1264.2%-1227.1%-10014.4%——
Operating Income(97.54M)(127.2M)(184.15M)(228.37M)(150.07M)
Operating Margin-1288.1%-1313.4%-11654.7%——
Interest Income272K4.67M24.08M21.09M0
Interest Expense0791K1.27M3.02M2.56M
Other Income / Expenses272K3.88M22.81M18.06M729K
Income Before Tax(97.26M)(123.32M)(161.34M)(210.3M)(149.34M)
Pre-Tax Margin-1284.5%-1273.3%-10211.1%——
Income Tax Expense00000
Net Income(97.26M)(123.32M)(161.34M)(210.3M)(149.34M)
Net Margin-1284.5%-1273.3%-10211.1%——
EPS (Basic)(2.71)(2.94)(2.75)(3.47)(2.43)
EPS (Diluted)(2.71)(2.94)(2.75)(3.47)(2.43)
Weighted Avg Shares35.85M42.02M58.72M60.54M61.37M
Weighted Avg Shares (Diluted)35.85M42.02M58.72M60.54M61.37M

Pliant Therapeutics, Inc.

NASDAQ:PLRX

Intrinsic Alpha fair value

Locked

Current Price

$0.81

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.